ECSP12011858A - Tratamiento de cáncer (es) resistente (s) a antagonistas de notch1 usando antagonistas de notch3 - Google Patents

Tratamiento de cáncer (es) resistente (s) a antagonistas de notch1 usando antagonistas de notch3

Info

Publication number
ECSP12011858A
ECSP12011858A ECSP12011858A ECSP12011858A EC SP12011858 A ECSP12011858 A EC SP12011858A EC SP12011858 A ECSP12011858 A EC SP12011858A EC SP12011858 A ECSP12011858 A EC SP12011858A
Authority
EC
Ecuador
Prior art keywords
antagonists
treatment
cancer
notch1
notch3
Prior art date
Application number
Other languages
English (en)
Inventor
Christian W Siebel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ECSP12011858A publication Critical patent/ECSP12011858A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento del cáncer en general y leucemia en particular, utilizando antagonistas de Notch1 y Notch3 solos o en combinación. También se proporcionan composiciones y métodos para el tratamiento y diagnóstico de tipos de cáncer asociados a Notch.
ECSP12011858 2009-09-30 2012-04-30 Tratamiento de cáncer (es) resistente (s) a antagonistas de notch1 usando antagonistas de notch3 ECSP12011858A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24729809P 2009-09-30 2009-09-30

Publications (1)

Publication Number Publication Date
ECSP12011858A true ECSP12011858A (es) 2012-06-29

Family

ID=43127684

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011858 ECSP12011858A (es) 2009-09-30 2012-04-30 Tratamiento de cáncer (es) resistente (s) a antagonistas de notch1 usando antagonistas de notch3

Country Status (21)

Country Link
US (1) US9200071B2 (es)
EP (1) EP2483311B1 (es)
JP (3) JP6025563B2 (es)
KR (1) KR101782180B1 (es)
CN (1) CN102630229B (es)
AU (1) AU2010300747A1 (es)
BR (1) BR112012007252A2 (es)
CA (1) CA2775880A1 (es)
CL (1) CL2012000800A1 (es)
CO (1) CO6531430A2 (es)
CR (1) CR20120213A (es)
EC (1) ECSP12011858A (es)
ES (1) ES2580229T3 (es)
HK (1) HK1170505A1 (es)
IL (1) IL218662A0 (es)
MA (1) MA33973B1 (es)
MX (1) MX342250B (es)
PE (1) PE20120998A1 (es)
RU (1) RU2012117619A (es)
WO (1) WO2011041336A2 (es)
ZA (1) ZA201201984B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8226943B2 (en) 2008-07-08 2012-07-24 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
JP6059985B2 (ja) 2009-06-18 2017-01-11 ファイザー・インク 抗ｎｏｔｃｈ−１抗体
RU2622083C2 (ru) 2010-12-15 2017-06-09 ВАЙЕТ ЭлЭлСи Антитела против notch1
TW201431880A (zh) 2012-11-07 2014-08-16 Pfizer 抗切口３（ａｎｔｉ－ｎｏｔｃｈ３）抗體及抗體－藥物共軛體
EP2935330B1 (en) 2012-12-19 2019-04-24 Aveo Pharmaceuticals, Inc. Anti-notch3 antibodies
EP2970479B1 (en) * 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
WO2014159242A1 (en) * 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
AU2014233736A1 (en) * 2013-03-15 2015-08-27 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
RS57608B1 (sr) * 2014-02-12 2018-11-30 Hoffmann La Roche Anti-jagged1 antitela i načini primene
US9914774B2 (en) 2014-07-11 2018-03-13 Genentech, Inc. Notch pathway inhibition
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
DK3448420T3 (da) * 2016-04-29 2022-12-12 Aveo Pharmaceuticals Inc Anti-notch3-antistof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
JP2008526205A (ja) 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
RU2461569C2 (ru) 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
PE20080891A1 (es) * 2006-10-19 2008-08-25 Genentech Inc Anticuerpos anti-notch3 y composiciones que los comprenden
TWI419904B (zh) * 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
CA2676008A1 (en) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20100062012A1 (en) 2007-03-05 2010-03-11 Ioannides Constantin G Negative Genetic Regulation of Cancer Cell Renewal in Synergy with Notch- or Numb-Specific Immunotherapy
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8226943B2 (en) * 2008-07-08 2012-07-24 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
JP6059985B2 (ja) * 2009-06-18 2017-01-11 ファイザー・インク 抗ｎｏｔｃｈ−１抗体

Also Published As

Publication number Publication date
EP2483311B1 (en) 2016-05-18
AU2010300747A1 (en) 2012-04-26
CN102630229B (zh) 2015-03-04
EP2483311A2 (en) 2012-08-08
KR20120100952A (ko) 2012-09-12
US20120328608A1 (en) 2012-12-27
JP6025563B2 (ja) 2016-11-16
CR20120213A (es) 2012-07-09
MX2012003851A (es) 2012-05-08
WO2011041336A2 (en) 2011-04-07
PE20120998A1 (es) 2012-08-14
CA2775880A1 (en) 2011-04-07
BR112012007252A2 (pt) 2020-08-11
ES2580229T3 (es) 2016-08-22
WO2011041336A3 (en) 2012-05-03
MA33973B1 (fr) 2013-02-01
MX342250B (es) 2016-09-22
IL218662A0 (en) 2012-05-31
ZA201201984B (en) 2013-05-29
US9200071B2 (en) 2015-12-01
JP2017014219A (ja) 2017-01-19
KR101782180B1 (ko) 2017-10-23
HK1170505A1 (en) 2013-03-01
JP2013506675A (ja) 2013-02-28
CN102630229A (zh) 2012-08-08
RU2012117619A (ru) 2013-11-10
JP2015145362A (ja) 2015-08-13
CO6531430A2 (es) 2012-09-28
CL2012000800A1 (es) 2012-08-31

Similar Documents

Publication Publication Date Title
ECSP12011858A (es) Tratamiento de cáncer (es) resistente (s) a antagonistas de notch1 usando antagonistas de notch3
PA8740901A1 (es) Compuestos organicos
DOP2013000267A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3
NI201200175A (es) Métodos de tratamiento de cáncer de vejiga
EA201171367A1 (ru) Винилиндазолильные соединения
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CR20120202A (es) Métodos y composiciones para tratar cáncer
CR20160173A (es) Nuevo tratamiento de combinación para la leucemia mieloide aguda (lma)
BR112015012987A2 (pt) composições compreendendo anticorpos anti-cd38 e lenalidomida
CO6480975A2 (es) Mimetico de smac
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CR20110509A (es) Composicion farmaceutica
EA201001639A1 (ru) Композиции и способы их получения и применения
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
GT201200123A (es) Nuevo uso antitumoral de cabazitaxel
ECSP11011054A (es) Péptidos antivirales terapéuticos
ECSP099574A (es) Agonistas adrenoreceptores alfa2c
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
ECSP11011558A (es) Nuevos compuestos químicos.
BR112015006705A2 (pt) antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CL2008001296A1 (es) Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres.
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения